1317 ET - Hims & Hers is hoping to take advantage of an FDA rule to be able to keep selling compounded versions of weight-loss drugs, even after the GLP-1 shortage has ended, Needham analyst Ryan MacDonald tells WSJ. The personalization exemption rule allows companies to sell compounds if they are personalizing the treatment for a patient; for example, if the patient needs to take an oral form instead of an injection. Hims hopes it can keep offering personalized compounds, as compounded drugs make up a significant portion of its weight-loss revenue, MacDonald says. But if the FDA finds this illegal, the company may be challenged to meet revenue goals, MacDonald says. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 13:17 ET (17:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。